CancerEXERT-CNCT06083324
EXErcise Regimen Designed to Improve Functional Mobility, Body Composition, and Strength After Treatment for Cancer
An observational study of Cancer, run by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) at 1 site in United States.
Trial summary
This protocol seeks to analyze patient outcomes of the standard of care, monitored group exercise regimen of high-load resistance training and functional exercises with compound movements under close supervision on individuals who have been treated for cancer. Read more about this study
- Who is it for?
- Ages 20 to 89 years
- Conditions the study is for
- Cancer
- What is being tested?
- Dose escalated resistance training
- How many people
- 100 participants
- Where
- 1 siteUnited States
- Study dates
- 3 Feb 2023to 16 Jan 2028
- How long will I take part?
- 3 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 89 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Individuals diagnosed with cancer on an exercise program at the AHN Exercise Oncology and Resiliency Center
Who may be able to join
- Age 20-89 years
- Women of child-bearing potential must verbally confirm lack of pregnancy prior to enrollment. They should also consent to use adequate contraception during the course of the study.
- Participants must be determined capable of engaging in resistance training by exercise personnel and/or study PI
- Participants must complete an assessment by EOC staff and be determined safe to engage in the workout regimen by the study exercise personnel.
- Individuals not deemed safe to participate in the standard EOC exercise program will be referred to physical therapy or elsewhere
Who cannot join
- 1. Severe arthritic, joint, cardiovascular, or musculoskeletal condition that would interfere with exercise program
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
AHN CI Exercise Oncology and Resiliency Center
Pittsburgh, Pennsylvania, 15202
Colin E Champ, MD, CSCS, 412-734-7605, colin.champ@ahn.org
Chris Peluso, BS
About this study
Official title: EXERT-C: Prospective Study of an EXErcise Regimen Designed to Improve Functional Mobility, Body Composition, and Strength After Treatment for Cancer
This protocol seeks to analyze patient outcomes of the standard of care, monitored group exercise regimen of high-load resistance training and functional exercises with compound movements under close supervision on individuals who have been treated for cancer.
- Conditions
- Cancer
- Being tested
- Dose escalated resistance training
- Keywords
- exercise, resistance training
- Medical subject headings
- Neoplasms, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dose escalated resistance trainingOther
All individuals will be engaging in resistance training during and/or after their cancer treatment
| Study group | Role | What they receive |
|---|---|---|
| General cancer patients | All patients undergoing treatment for cancer on an exercise regimen Receives: Other: Dose escalated resistance training | |
| Head and neck cancer patients | All patients undergoing treatment for head and neck cancer on an exercise regime Receives: Other: Dose escalated resistance training | |
| Colorectal cancer patients | All patients undergoing treatment for colorectal cancer on an exercise regime Receives: Other: Dose escalated resistance training | |
| Pancreatic cancer patients | All patients undergoing treatment for pancreatic cancer on an exercise regime Receives: Other: Dose escalated resistance training | |
| Metastatic breast cancer patients | All patients undergoing treatment for metastatic breast cancer on an exercise regime Receives: Other: Dose escalated resistance training |
What is being measured
The primary outcome is the main question the study is designed to answer.
Determine changes in fat mass in pounds from before to after the nutrition and exercise regimen via bioimpedance analysis
Measurement on bioimpedance analysis machine (Inbody 970)
Measured: 3 months
Determine changes in fat mass in pounds from before to after the nutrition and exercise regimen via ultrasound
Measurement via ultrasound and calculation with Jackson-Pollack calculations
Measured: 3 months
Determine changes in muscle mass in pounds from before to after the nutrition and exercise regimen
Measurement on bioimpedance analysis machine (Inbody 970)
Measured: 3 months
Secondary outcomes (4)
Determine changes in overall score of functional movement screen (FMS) from before to after the nutrition and exercise regimen
Determine changes in overall score of functional movement screen (FMS) from before to after the nutrition and exercise regimen
Measured: 3 months
Determine changes in Y-balance score for each leg
Y-balance score adds up the distance each leg can move in the front and side directions, divided by the length of the hip. This correlates inversely with fall risk.
Measured: 3 months
Determine changes in strength via load measured in pounds from before to after the nutrition and exercise regimen
Load is calculated by multiplying sets by repetitions by weight lifted for a specific exercise
Measured: 3 months
Determine changes in EQ-5D responses 1-5 and overall score from before to after the nutrition and exercise regimen
EQ-5D asks 5 questions rates from 1-5 and an overall rating of health
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Oct 2023
- Study start3 Feb 2023
- Primary completion16 Jan 2027 (estimated)
- Study completion16 Jan 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
- Target duration
- 3 Months
Sponsor and investigators
- Lead sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Colin Champ, MD, Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06083324
- Sponsor's protocol ID
- 2023-021-SG
- Acronym
- EXERT-C
- Status last verified
- Jul 2026
- First submitted
- 9 Oct 2023
- Last updated
- 8 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Champ CE, Carpenter DJ, Diaz AK, Rosenberg J, Ackerson BG, Hyde PN. Resistance Training for Patients with Cancer: A Conceptual Framework for Maximizing Strength, Power, Functional Mobility, and Body Composition to Optimize Health and Outcomes. Sports Med. 2023 Jan;53(1):75-89. doi: 10.1007/s40279-022-01759-z. Epub 2022 Sep 29.
PubMed 36175646
Study at a glance
From the registry record, last updated by the sponsor on 8 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- EXERT-C: Prospective Study of an EXErcise Regimen Designed to Improve Functional Mobility, Body Composition, and Strength After Treatment for Cancer
- ClinicalTrials.gov ID
- NCT06083324
- Acronym / sponsor ID
- EXERT-C / 2023-021-SG
- Conditions
- Cancer
- Keywords
- exercise, resistance training
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)University, hospital or other
- Study start
- 3 Feb 2023 (actual)
- Primary completion
- 16 Jan 2027 (estimated)
- Study completion
- 16 Jan 2028 (estimated)
- First posted
- 16 Oct 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This protocol seeks to analyze patient outcomes of the standard of care, monitored group exercise regimen of high-load resistance training and functional exercises with compound movements under close supervision on individuals who have been treated for cancer.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 3 Months
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| General cancer patients | – | Other: Dose escalated resistance trainingAll patients undergoing treatment for cancer on an exercise regimen |
| Head and neck cancer patients | – | Other: Dose escalated resistance trainingAll patients undergoing treatment for head and neck cancer on an exercise regime |
| Colorectal cancer patients | – | Other: Dose escalated resistance trainingAll patients undergoing treatment for colorectal cancer on an exercise regime |
| Pancreatic cancer patients | – | Other: Dose escalated resistance trainingAll patients undergoing treatment for pancreatic cancer on an exercise regime |
| Metastatic breast cancer patients | – | Other: Dose escalated resistance trainingAll patients undergoing treatment for metastatic breast cancer on an exercise regime |
Who may qualify
- Ages
- 20 to 89 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Individuals diagnosed with cancer on an exercise program at the AHN Exercise Oncology and Resiliency Center
Key inclusion criteria (5 listed)
- Age 20-89 years
- Women of child-bearing potential must verbally confirm lack of pregnancy prior to enrollment. They should also consent to use adequate contraception during the course of the study.
- Participants must be determined capable of engaging in resistance training by exercise personnel and/or study PI
- Participants must complete an assessment by EOC staff and be determined safe to engage in the workout regimen by the study exercise personnel.
- Individuals not deemed safe to participate in the standard EOC exercise program will be referred to physical therapy or elsewhere
Key exclusion criteria (1 listed)
- 1. Severe arthritic, joint, cardiovascular, or musculoskeletal condition that would interfere with exercise program
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dose escalated resistance trainingAll individuals will be engaging in resistance training during and/or after their cancer treatment | Other | Colorectal cancer patients, General cancer patients, Head and neck cancer patients, Metastatic breast cancer patients, Pancreatic cancer patients |
Primary outcome
Determine changes in fat mass in pounds from before to after the nutrition and exercise regimen via bioimpedance analysis
Time frame: 3 months
Measurement on bioimpedance analysis machine (Inbody 970)
Determine changes in fat mass in pounds from before to after the nutrition and exercise regimen via ultrasound
Time frame: 3 months
Measurement via ultrasound and calculation with Jackson-Pollack calculations
Determine changes in muscle mass in pounds from before to after the nutrition and exercise regimen
Time frame: 3 months
Measurement on bioimpedance analysis machine (Inbody 970)
4 secondary outcomes
Determine changes in overall score of functional movement screen (FMS) from before to after the nutrition and exercise regimen
Time frame: 3 months
Determine changes in Y-balance score for each leg
Time frame: 3 months
Determine changes in strength via load measured in pounds from before to after the nutrition and exercise regimen
Time frame: 3 months
Determine changes in EQ-5D responses 1-5 and overall score from before to after the nutrition and exercise regimen
Time frame: 3 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jul 2026.
- Background: PubMed 36175646Champ CE, Carpenter DJ, Diaz AK, Rosenberg J, Ackerson BG, Hyde PN. Resistance Training for Patients with Cancer: A Conceptual Framework for Maximizing Strength, Power, Functional Mobility, and Body Composition to Optimize Health and Outcomes. Sports Med. 2023 Jan;53(1):75-89. doi: 10.1007/s40279-022-01759-z. Epub 2022 Sep 29.
- Individual participant dataSharing planned: Undecided
Related trials for Cancer
Enrolling by invitation
Exercise Intervention for Breast Cancer Patients With Sarcopenia
Sarcopenia, Breast Cancer
RecruitingPhase 3
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
IO Resistant Squamous and Nonsquamous NSCLC
Not yet recruitingPhase 2
Saruparib in HRDsig+ Solid Tumors
Malignant Neoplastic Disease (Disorder)
RecruitingPhase 2
IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence
Fallopian Tube Carcinoma, Ovarian Carcinoma
Not yet recruitingPhase 2
Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor
Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer, run by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 8 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Samantha Campbell ((412) 330-6151, samantha.campbell@ahn.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Determine changes in fat mass in pounds from before to after the nutrition and exercise regimen via bioimpedance analysis (time frame: 3 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06083324, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jul 2026; AzTrials last refreshed its copy on 3 Nov 2026.